TopBuild: Big Moves Don't Justify An Upgrade...Yet (NYSE:BLD)
Seeking Alpha· 2025-12-30 04:25
服务介绍 - 提供专注于石油和天然气的投资服务和社区 [1] - 服务核心关注现金流及其创造公司 旨在发掘具有真实潜力的价值和增长前景 [1] - 订阅者可使用一个包含50多只股票的投资组合模型账户 [1] 服务内容 - 提供对勘探与生产公司的深入现金流分析 [1] - 提供关于该行业的实时聊天讨论 [1] 订阅优惠 - 提供为期两周的免费试用 [2]
Two airlines nearly collide taking off from Houston's Bush Intercontinental Airport
Fox Business· 2025-12-30 04:25
事件概述 - 12月18日当地时间约15:05 一架Volaris航空飞往萨尔瓦多的航班在休斯顿布什洲际机场起飞后 未经授权右转 切入了一架飞往密西西比州杰克逊的联合快运航班路径 险些发生碰撞[1][5] - 空中交通管制指示Volaris航班4321左转 但机组人员却右转 转向从平行跑道起飞的CommuteAir航班814[2] - 美国联邦航空管理局正在对此事件进行调查[1][5] 涉及公司情况 - 涉事的CommuteAir航班814由联合快运运营 联合航空是CommuteAir的部分所有者[2] - CommuteAir初步评估称其机组遵守了所有适用的空中交通管制指令[6] - Volaris航空的股票代码为VLRS 股价为9.22美元 当日下跌0.65%[6] - 联合航空的股票代码为UAL 股价为114.04美元 当日下跌0.67%[6] 行业背景与安全状况 - 休斯顿洲际机场平均每天有500架抵达航班 每年旅客抵达量超过2000万人次[11] - 尽管航空业接近碰撞和相关安全事件有所增加 但美国交通部长表示飞行是安全的 并在圣诞假期前重申了这一信息[11] - 交通部长表示 在之前政府停摆的最后几天 已将航空公司运力削减了10% 并将采取一切必要措施确保空域安全[12]
Tesla Q4 Deliveries Face Steep Slump, Gene Munster Warns; Adds Real Value Now Lies In Physical AI
Benzinga· 2025-12-30 04:23
核心观点 - 特斯拉第四季度汽车交付量预计将显著低于市场共识和去年同期水平 但市场关注点正从传统汽车交付量转向其人工智能和机器人出租车等业务 这可能导致交付量不及预期对股价波动的影响减弱 [1][6][7] 第四季度交付预期与市场表现 - 分析师Gene Munster预计特斯拉第四季度交付量约为41.5万辆 这较去年同期的49.557万辆同比下降16% 也低于市场普遍预期的约44.9万辆 [3] - 第三季度因美国联邦税收抵免政策于9月30日到期 刺激需求前置 特斯拉录得创纪录的49.7099万辆交付量 这加剧了第四季度交付量的环比下滑压力 [3] - 尽管交付量预计下滑 但特斯拉可能在第四季度获得市场份额 因行业数据显示美国电动汽车当季销量预计同比下降30% 若特斯拉交付量仅下降16% 则意味着其表现优于困境中的同行 [5] 投资者关注点转移 - 分析师和专家越来越强调特斯拉的人工智能和机器人出租车业务 而非汽车交付量 这或将最小化因交付数据不及预期而引发的股价大幅波动 [6] - 投资者对2026年全年及第四季度交付量的预期已有所下降 原因在于市场对特斯拉在实体人工智能领域的投资前景日益乐观 这主要由其全自动驾驶、机器人出租车和Optimus人形机器人所驱动 [7] - 市场专家认为 特斯拉当前1.6万亿美元的市值可能反映了相对于单一汽车业务的“分类加总估值法”溢价 鉴于其在实体AI领域的领导地位 其估值目标应更接近4万亿美元而非1万亿美元 [8] 未来展望与业务稳定性 - 第四季度交付数据公布后 下一个关键数据将是2026年的交付量预期 Munster预测其年增长率将持平至增长5% 低于市场共识的13%同比增长预期 [9][10] - 特斯拉在2025年全年交付量可能下降约8%之后 明年只需展示交付量已趋于稳定即可 [10] - 长期来看 随着竞争对手减少对电动汽车领域的投入 特斯拉的汽车交付量有望实现15%或更高的年增长率 [10] - 过去六个月以及自公司上次于10月2日报告交付数据以来 特斯拉股价表现优于纳斯达克指数 [8]
Intel Stock Has Soared Since Its Dow Ouster — Even Outrunning Nvidia, Its Replacement - Intel (NASDAQ:INTC)
Benzinga· 2025-12-30 04:15
Intel Corporation (NASDAQ:INTC) had a 2024 to forget. The chipmaker lost more than 50% of its market value, and its stock was kicked out of the Dow Jones Industrial Average after 25 years. One year later, the picture looks very different.Intel shares are now trading at sharply higher levels. What’s ahead for INTC stock?Intel’s Big ComebackAfter 25 years in the Dow Jones Industrial Average, which is tracked by the SPDR Dow Jones Industrial Average ETF Trust (NYSE:DIA) , Intel was removed and replaced by semi ...
Should You Buy Nu Holdings (NU) Stock Before February?
The Motley Fool· 2025-12-30 04:15
The high-growth fintech company has a bright future ahead.Nu Holdings (NU 0.83%), one of Latin America's fastest-growing fintech companies, has seen its stock rally more than 50% over the past 12 months. It impressed the market with its robust growth in customers, revenue, and earnings.Should you buy Nu's stock before it posts its fourth-quarter earnings report in February? Let's review its business model, growth rates, and valuations to determine the answer. How rapidly is Nu growing?Nu's NuBank is the lar ...
Intel Stock Has Soared Since Its Dow Ouster — Even Outrunning Nvidia, Its Replacement
Benzinga· 2025-12-30 04:15
Intel Corporation (NASDAQ:INTC) had a 2024 to forget. The chipmaker lost more than 50% of its market value, and its stock was kicked out of the Dow Jones Industrial Average after 25 years. One year later, the picture looks very different.Intel shares are now trading at sharply higher levels. What’s ahead for INTC stock?Intel’s Big ComebackAfter 25 years in the Dow Jones Industrial Average, which is tracked by the SPDR Dow Jones Industrial Average ETF Trust (NYSE:DIA) , Intel was removed and replaced by semi ...
Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today
The Motley Fool· 2025-12-30 04:14
A pharmaceutical company's success with a Phase 2 study doesn't guarantee positive results in Phase 3.Heading into 2026 on an inauspicious note, Ultragenyx Pharmaceuticals (RARE 43.70%), a pharmaceutical company specializing in treatments for rare and ultra-rare genetic diseases, announced disappointing results from its Phase 3 studies for setrusumab (UX143). Add in a flurry of analysts slashing their price targets on Ultragenyx stock, and it's clear why investors are clicking the sell button today.As of 2: ...
Costco's 2025: 3 Things Investors Should Know Heading Into the New Year
The Motley Fool· 2025-12-30 04:05
Costco didn't have a headline-grabbing year in 2025, and that's precisely what the company intended.Costco Wholesale (COST 0.65%) ended 2025 in a familiar position: operationally strong, strategically disciplined, and still trading at a premium that divides investors. While the stock didn't outperform the broader market this year, the underlying business continued to execute in ways that reinforce why Costco remains one of the most closely watched names in retail.As investors look ahead, three themes from 2 ...
Union Pacific–Norfolk Southern Merger Targets Trucking Market Share
Barrons· 2025-12-30 04:02
The railroads say their proposed tie-up would shift millions of truckloads to rail, boosting competition while cutting pollution and congestion. ...
Five Things to Know About Nvidia's $20 Billion Licensing Deal
WSJ· 2025-12-30 04:02
行业动态 - 芯片制造商与初创公司Groq达成人工智能推理协议 表明行业对顶尖人才和技术的竞争日益加剧 [1]